ClinicalTrials.gg
CompletedNCT01709708Tx360Updated Jan 26, 2018Results posted

Use of the Tx360 Nasal Applicator in the Treatment of Chronic Migraine

A Phase 4 interventional study of Marcaine and Saline in Chronic Migraine, sponsored by Tian Medical Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-01-26.

Sponsored by Tian Medical Inc. · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing bupivacaine in Migraine Disorders — 4 open to participants now, 4 under way, 1 of them phase 3. Bupivacaine · Migraine Disorders.

Enrollment
10th of 14
41 · median 55
Started
2012
with 1 other
Phase 4
5 of 14
1 open now
Registered
2nd of 14
by date

Among the 14 studies testing bupivacaine in Migraine Disorders, this one is the 10th largest by enrollment, is one of 2 that started in 2012, is one of 5 in phase 4, and was the 2nd registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

4 of the 14 studies testing bupivacaine in Migraine Disorders are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing bupivacaine in Migraine Disorders, or all of them as a file.
02

Study summary

Migraine imposes a substantial burden on patients in terms of diminished daily functioning, quality of life, and financial loss. Pain severity and duration correlates with reduced measures of daily functioning, and overall health status. The sphenopalatine ganglion (SPG) has been implicated in a variety of cephalalgias. This has been well represented in the literature dating back over a century. Access to this structure can be gained via a small area of mucosa just posterior and superior to the tail of the middle turbinate on the lateral nasal wall. At this aspect, there is no bony boundary to the SPG. Blocking the SPG using local anesthetics relieves pain. Unfortunately, many current interventions are cumbersome, invasive, and expensive. The purpose of this study is to evaluate the efficacy of the Tx360™, a new nasal applicator device, in the treatment of head and face pain and to examine the economic implications. The Tx360™ is a single use device designed to deliver a topical local anesthetic to the specific area of mucosa associated with the SPG. A total of 42 study participants will be accepted into this double-blind placebo-controlled study. 28 will receive SPG blocks using a 0.3 mL of a 0.5% solution of Marcaine delivered by the Tx360™ while 14 will receive a placebo of saline substituted for the Marcaine. Both patient sets will also be given a piece of lemon hard candy as a taste distractor. Participants must have a chronic migraine history with over 15 symptomatic days per month over the past three months. The treatment plan consists of six weeks of treatment, two times per week. Short and longer term assessments will be retrieved and analyzed as detailed in the Study Design.

Read the detailed description

42 study participants will be included in this double-blind placebo-controlled study. Following enrollment of 42 subjects and completion of the 6-week Treatment Period by all active subjects, an analysis of the treatment effect will be performed for a reassessment of sample size and, if deemed appropriate, the study will continue with enrollment of additional subjects to ensure a more statistically robust interpretation of the data. The results of the statistical analysis will be blinded from Investigators and coordinators. The procedure will be delivered to all subjects who agree to participate, meet inclusion criteria, and sign informed consent.

At Visit 1 following Informed Consent, a physical exam and vital signs will be completed. A medical, headache, and medication history (to include age, sex, height and weight, and duration and location of headache pain, as well as history of ER visits) will be collected on all subjects. Eligible subjects will be provided with a Baseline Headache Diary and instructed to treat migraines for the following month in their usual manner with their usual treatment. The daily Diary will document headache, acute treatment and response, and migraine associated symptoms (nausea, vomiting, light sensitivity, or sound sensitivity) to establish a Baseline number of headache days and severity. Visit 2 will be scheduled for 1 month following Visit 1. Following Visit 1, Visits 2-13 (treatment visits) will be scheduled to occur twice weekly (during the regular Monday - Friday work week) at least 2 days apart. Treatments should not occur on consecutive days.

At Visit 2, the Baseline Headache Diary will be reviewed and those subjects continuing to meet eligibility will be dispensed a 6-week Treatment Period Diary and complete Before Procedure questions to include the Pain Intensity Numeric Rating Scale (NRS), the Modified Pain Characteristic Questionnaire, and a baseline Headache Impact Test-6 (HIT-6), have vital signs completed, and the medical, headache, and medication history updated. Subjects will be randomized 2:1 to Group A or Group B. Group A will receive treatment with 0.3 mL of 0.5% Marcaine delivered bilaterally with the Tx360™ device to the mucosa associated with the SPG. Group B will receive saline substituted for Marcaine delivered bilaterally with the Tx360TM device to the mucosa associated with the SPG.

To maintain the blinding of the treatment groups, neither the Investigator nor research personnel who are involved in evaluating the subject should prepare the study medication. An independent research staff person with no involvement in the study conduct will place study medication (either Marcaine for a subject randomized to Group A or Placebo/saline for a subject randomized to Group B) in a 1cc Luer Lok tip syringe and assemble the syringe and Tx360TM catheter as instructed in training. A label with the subject Drug Number will be placed on the device at that time. The research staff person administering the study medication will verify that the Drug Number assignment is correct.

Both Groups will be given a piece of lemon hard candy as a taste distractor.

At each treatment visit (Visits 2-13), in addition to Before Procedure questions, subjects will complete 15-minute and 30-minute After Procedure questionnaires to include the NRS and, at 30 minutes, the Patient's Global Impression of Change (PGIC). Subjects will take home a questionnaire to include the NRS, PGIC, satisfaction question, and the Modified Pain Characteristic Questionnaire to be completed at 24 hours following treatment and be instructed to return the 24-hour After Procedure questionnaire to the clinic at the next visit.

At Visits 2-15 vital signs will be completed, medications will be updated, and Non-Serious Adverse Events will be collected after the first treatment. Serious Adverse Events will be collected once the informed consent has been signed and throughout the study.

At Visits 5, 8, and 11, the Treatment Period Headache Diary will be collected, reviewed, and re-dispensed.

At Visit 13, the 1-Month Post-Treatment Period Diary will be dispensed.

The subject will return to the clinic at Visit 14 between 24 and 96 hours following the final treatment at Visit 13 to return the 24-hour After Procedure Questionnaire and complete the 1-Month Treatment Period HIT-6. The Treatment Period Diary will be collected.

At Visit 15, 1 month following the final treatment, each subject will return to the clinic and complete a 1-Month Follow Up HIT-6 and the 1-Month Follow Up Questionnaire. The 1-Month Post-Treatment Period Diary will be collected.

At 6 months following the final treatment, each subject will be phoned to complete the 6-Month Follow Up Questionnaire to include the NRS, PGIC, satisfaction question, the Modified Pain Characteristic Questionnaire, and a 6-Month Follow Up HIT-6.

Treatment Medication Subjects randomized to Group A will be administered 0.3 mL of 0.5% Marcaine delivered bilaterally with the Tx360™ device to the mucosa associated with the SPG. Twelve treatments will be administered over a period of 6 weeks.

Subjects randomized to Group B will be administered saline substituted for Marcaine delivered bilaterally with the Tx360TM device to the mucosa associated with the SPG for treatment of chronic migraine. Twelve treatments will be administered over a period of 6 weeks.

Rescue Medication Subjects will be allowed to rescue with medication mutually agreed upon by subject and Investigator at the time of screening.

03

Conditions studied

  • Chronic Migraine

Keywords

  • Migraine
  • Headache
  • Chronic Migraine
  • Marcaine
  • Tx360
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is male or female, in otherwise good health, 18 to 80 years of age.
  2. Has history of chronic migraine (with or without aura) according to the criteria proposed by the Headache Classification Committee of the International Headache Society for at least 3 months prior to enrollment.
  3. Has onset of migraine before age 50.
  4. Is able to differentiate migraine from any other headache they may experience (e.g., tension-type headache).
  5. Is not currently taking a migraine preventive or has been taking preventive for at least 30 days prior to screening and agrees to not start, stop, or change medication and/or dosage during the study period.
  6. If female of , agrees to use, for the duration of the study, a medically acceptable form of as determined by the Investigator.

    1. Complete abstinence from intercourse from 2 weeks prior to administration of study drug throughout the study, and for a time interval after completion or premature discontinuation from the study to account for elimination of the study drug; or,
    2. Surgically sterile (hysterectomy or tubal ligation or otherwise incapable of pregnancy); or,
    3. Sterilization of male partner; or,
    4. Intrauterine device with published data showing lowest expected failure rate is less than 1% per year; or,
    5. Double barrier method (i.e., 2 physical barriers OR 1 physical barrier plus spermicide) for a least 1 month prior to Visit 1 and throughout study; or,
    6. Hormonal contraceptives for at least 3 months prior to Visit 1 and throughout study.
  7. Has pain presentation in frontal, temporal, ophthalmic, maxillary, mandibular, facial, or intraoral location.

Exclusion criteria

Exclusion Criteria:

  1. Is male or female, in otherwise good health, 18 to 80 years of age.
  2. Has history of chronic migraine (with or without aura) according to the criteria proposed by the Headache Classification Committee of the International Headache Society for at least 3 months prior to enrollment.
  3. Has onset of migraine before age 50.
  4. Is able to differentiate migraine from any other headache they may experience (e.g., tension-type headache).
  5. Is not currently taking a migraine preventive or has been taking preventive for at least 30 days prior to screening and agrees to not start, stop, or change medication and/or dosage during the study period.
  6. If female of , agrees to use, for the duration of the study, a medically acceptable form of as determined by the Investigator.

    1. Complete abstinence from intercourse from 2 weeks prior to administration of study drug throughout the study, and for a time interval after completion or premature discontinuation from the study to account for elimination of the study drug; or,
    2. Surgically sterile (hysterectomy or tubal ligation or otherwise incapable of pregnancy); or,
    3. Sterilization of male partner; or,
    4. Intrauterine device with published data showing lowest expected failure rate is less than 1% per year; or,
    5. Double barrier method (i.e., 2 physical barriers OR 1 physical barrier plus spermicide) for a least 1 month prior to Visit 1 and throughout study; or,
    6. Hormonal contraceptives for at least 3 months prior to Visit 1 and throughout study.
  7. Has pain presentation in frontal, temporal, ophthalmic, maxillary, mandibular, facial, or intraoral location.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
41 participants (actual)

Study arms

  • Active comparator
    Marcaine

    Group A will receive treatment with 0.3 mL of 0.5% Marcaine delivered bilaterally with the Tx360™ device to the mucosa associated with the Sphenopalatine Ganglion (SPG)

    Drug: Marcaine

  • Placebo comparator
    Saline

    Group B will receive saline placebo delivered bilaterally with the Tx360TM device to the mucosa associated with the SPG.

    Drug: Saline

Interventions

  • Marcaine used as a topical local anesthetic to block the SPG by delivering Marcaine directly to the specific area of mucosa associated with the SPG.

    Also known as: Bupivicane (generic)

  • DrugSaline

    Saline

06

What researchers measure

Primary outcomes

  1. Numeric Rating Scale (NRS)

    Compare Numeric Rating Scale (NRS) scores Before Procedure,15-Minute Post Treatment, 30-Minutes Post Treatment, 24-Hour Post Treatment for all 12 treatments (Marcaine vs. Saline). NRS is a likert scale ranging from 0-10 with 0 being no pain and 10 being worst possible pain. For each individual time point, all 12 treatments were averaged for that time point and a single value was used for comparison between the two groups.

    Time frame: 6 Weeks

Secondary outcomes

  1. Change in Numeric Rating Scale (NRS)

    Compare percentage change in Numeric Rating Scale (NRS) score from Before Procedure to 15-Minutes, Before Procedure to 30-Minutes, Before Procedure to 24-Hours After Procedure for all 12 treatments (Mean of all 12 treatments for each timepoint, comparing Group A to Group B). NRS is a likert scale ranging from 0-10 with 0 being no pain and 10 being worst possible pain.

    Time frame: 15 Minutes Post Treatment, 30 minutes Post Treatment and 24 hours Post Treatment, assessed up to 6 weeks

  2. Patient's Global Impression of Change (PGIC)

    Compare 24-Hour After Procedure Patient's Global Impression of Change (PGIC) score for 12 treatments (Mean of all 12 treatments for each timepoint, comparing Group A to Group B). PGIC is a likert scale ranging from 1 to 7 with 1 being very much improved and 7 being very much worse.

    Time frame: 30 minutes Post Treatment and 24 hours Post Treatment, assessed up to 6 weeks

  3. Modified Pain Characteristic Questionnaire

    Compare Modified Pain Characteristic Questionnaire scores Before Procedure vs. 24-Hour After Procedure, Before Procedure vs. 1-Month Follow Up, and Before Procedure vs. 6-Month Follow Up (Mean of all 12 treatments for each timepoint, comparing Group A to Group B). The modified pain characteristic questionnaire is a series of 11 questions on a likert scale ranging from 0 to 10 with 0 being no pain or does not interfere and 10 being worst pain or completely interferes. Percentage questions range from 0 to 100.

    Time frame: Before Treatment, 24 Hours After Treatment, 1 Month Post Treatment, and 6 Months Post Treatment

  4. Migraine Headache Days

    Compare change in the number of migraine headache days per month reported in Baseline Period Diary vs. Treatment Period Diary vs. Post-Treatment Period Diary.

    Time frame: 12 Weeks

  5. Acute Medications Usage

    Number of acute medications used during Treatment period (6 weeks) and Follow-Up (4 weeks) (Group A vs. Group B).

    Time frame: 10 Weeks

  6. Adverse Events

    Number of adverse events over the entire length of study (Group A vs. Group B).

    Time frame: 34 weeks

  7. Headache Impact Test (HIT-6)

    Total Headache Impact Test (HIT-6) scores Pre-Treatment at Visit 2 vs. Post-Treatment (following final treatment), and at 1-Month Post-Treatment (Group A vs. Group B). HIT-6 is a series of 6 likert scale questions ranging from 1 to 5 with 1 being never and 5 being always. The HIT-6 answer options are weighted as follows: Never (1) = 6 points each, Rarely (2) = 9 points each, Sometimes (3) = 10 points each, Very often (4) = 11 points each, Always (5) = 13 points each. The total score for the HIT-6 ranges from 36 (subject answers all 6 questions as "Never") to 78 subject answers all 6 questions as "Always"), with higher total scores indicating more impact than lower scores, i.e., headaches cause greater impact on the subject's life.

    Time frame: 10 Weeks

  8. Overall Satisfaction

    Satisfaction scores Visit 2 vs. following treatment (Treatment 12) and at 1-Month Post-Treatment (Group A vs. Group B). Satisfaction scores are a likert scale ranging from 1 to 5 with 1 being complete dissatisfaction and 5 being complete satisfaction.

    Time frame: 10 Weeks

07

Results

Posted Oct 20, 2014

Participant flow

Participant flow — Overall Study
MilestoneMarcaineSaline
Started2714
Completed2612
Not completed12
Withdrew: Protocol violation12

Outcome measures

PrimaryNumeric Rating Scale (NRS)

Compare Numeric Rating Scale (NRS) scores Before Procedure,15-Minute Post Treatment, 30-Minutes Post Treatment, 24-Hour Post Treatment for all 12 treatments (Marcaine vs. Saline). NRS is a likert scale ranging from 0-10 with 0 being no pain and 10 being worst possible pain. For each individual time point, all 12 treatments were averaged for that time point and a single value was used for comparison between the two groups.

Time frame:
6 Weeks
Reported as:
Mean · units on a scale
Numeric Rating Scale (NRS)
units on a scaleMarcaineSaline
Before Procedure3.18 ± 2.793.78 ± 2.48
15 Minutes Post Treatment2.53 ± 2.613.51 ± 2.39
30 Minutes Post Treatment2.41 ± 2.613.45 ± 2.36
24 Hours Post Treatment2.85 ± 2.744.20 ± 2.62
SecondaryChange in Numeric Rating Scale (NRS)

Compare percentage change in Numeric Rating Scale (NRS) score from Before Procedure to 15-Minutes, Before Procedure to 30-Minutes, Before Procedure to 24-Hours After Procedure for all 12 treatments (Mean of all 12 treatments for each timepoint, comparing Group A to Group B). NRS is a likert scale ranging from 0-10 with 0 being no pain and 10 being worst possible pain.

Time frame:
15 Minutes Post Treatment, 30 minutes Post Treatment and 24 hours Post Treatment, assessed up to 6 weeks
Reported as:
Mean · percentage of change
Change in Numeric Rating Scale (NRS)
percentage of changeMarcaineSaline
15 Minutes Post Treatment-23.3 ± 34.5-4.31 ± 27.3
30 Minutes Post Treatment-27.7 ± 37.1-5.41 ± 29.2
24 Hours Post Treatment-15.5 ± 69.913.5 ± 78.8
SecondaryPatient's Global Impression of Change (PGIC)

Compare 24-Hour After Procedure Patient's Global Impression of Change (PGIC) score for 12 treatments (Mean of all 12 treatments for each timepoint, comparing Group A to Group B). PGIC is a likert scale ranging from 1 to 7 with 1 being very much improved and 7 being very much worse.

Time frame:
30 minutes Post Treatment and 24 hours Post Treatment, assessed up to 6 weeks
Reported as:
Mean · units on a scale
Patient's Global Impression of Change (PGIC)
units on a scaleMarcaineSaline
30 Minutes Post Treatment3.00 ± 1.023.72 ± 0.53
24 Hours Post Treatment3.08 ± 1.263.88 ± 1.02
SecondaryModified Pain Characteristic Questionnaire

Compare Modified Pain Characteristic Questionnaire scores Before Procedure vs. 24-Hour After Procedure, Before Procedure vs. 1-Month Follow Up, and Before Procedure vs. 6-Month Follow Up (Mean of all 12 treatments for each timepoint, comparing Group A to Group B). The modified pain characteristic questionnaire is a series of 11 questions on a likert scale ranging from 0 to 10 with 0 being no pain or does not interfere and 10 being worst pain or completely interferes. Percentage questions range from 0 to 100.

Time frame:
Before Treatment, 24 Hours After Treatment, 1 Month Post Treatment, and 6 Months Post Treatment
Reported as:
Mean · units on a scale
Modified Pain Characteristic Questionnaire
units on a scaleMarcaineSaline
Worst Pain Question: Before Treatment4.75 ± 3.116.15 ± 2.65
Worst Pain Question: 24 Hours After Treatment4.36 ± 3.016.16 ± 2.44
Worst Pain Question: 1 Month Post Treatment4.56 ± 3.235.64 ± 3.04
Worst Pain Question: 6 Months Post Treatment4.27 ± 3.105.88 ± 1.73
Least Pain Question: Before Treatment2.01 ± 2.552.50 ± 2.13
Least Pain Question: 24 Hours After Treatment1.77 ± 2.492.43 ± 1.93
Least Pain Question: 1 Month Post Treatment1.88 ± 2.622.64 ± 2.11
Least Pain Question: 6 Months Post Treatment1.68 ± 2.032.88 ± 2.47
Average Pain Question: Before Treatment3.39 ± 2.614.33 ± 2.29
Average Pain Question: 24 Hours After Treatment3.07 ± 2.574.27 ± 2.09
Average Pain Question: 1 Month Post Treatment3.36 ± 2.873.91 ± 2.30
Average Pain Question: 6 Months Post Treatment2.86 ± 2.624.00 ± 2.27
Percent Relief Question: Before Treatment41.3 ± 36.529.2 ± 33.0
Percent Relief Question: 24 Hours After Treatment46.0 ± 38.229.8 ± 32.5
Percent Relief Question: 1 Month Post Treatment46.3 ± 39.921.0 ± 32.1
Percent Relief Question: 6 Months Post Treatment34.7 ± 29.218.6 ± 30.8
General Activity Question: Before Treatment2.49 ± 2.963.50 ± 2.70
General Activity Question: 24 Hours After Treatmen2.31 ± 2.903.64 ± 2.78
General Activity Question: 1 Month Post Treatment2.64 ± 2.913.91 ± 2.81
General Activity Question: 6 Months Post Treatment2.68 ± 2.874.00 ± 3.32
Mood Interference Question: Before Treatment2.57 ± 3.073.78 ± 2.84
Mood Interference Question: 24 Hours After Treatme2.42 ± 3.064.19 ± 3.04
Mood Interference Question: 1 Month Post Treatment2.96 ± 3.433.82 ± 3.40
Mood Interference Question: 6 Months Post Treatmen3.18 ± 3.265.71 ± 3.68
Walking Ability Question: Before Treatment0.63 ± 1.271.27 ± 2.24
Walking Ability Question: 24 Hours After Treatment0.54 ± 1.331.24 ± 2.37
Walking Ability Question: 1 Month Post Treatment0.80 ± 1.680.55 ± 0.93
Walking Ability Question: 6 Months Post Treatment0.45 ± 1.740.43 ± 1.13
Normal Work Question: Before Treatment2.53 ± 3.083.49 ± 2.81
Normal Work Question: 24 Hours After Treatment2.21 ± 3.023.63 ± 2.97
Normal Work Question: 1 Month Post Treatment2.52 ± 3.143.45 ± 2.94
Normal Work Question: 6 Months Post Treatment2.59 ± 2.773.71 ± 3.50
Relationships Question: Before Treatment2.00 ± 2.873.47 ± 2.92
Relationships Question: 24 Hours After Treatment1.96 ± 2.873.90 ± 3.09
Relationships Question: 1 Month Post Treatment2.36 ± 3.293.09 ± 3.45
Relationships Question: 6 Months Post Treatment2.05 ± 2.873.86 ± 3.98
Sleep Interference Question: Before Treatment2.29 ± 3.092.68 ± 3.11
Sleep Interfere Question: 24 Hours After Treatment1.89 ± 3.032.85 ± 3.22
Sleep Interferenc Question: 1 Month Post Treatment1.92 ± 3.002.55 ± 3.47
Sleep Interference Question: 6 Months Post Treatme1.55 ± 2.323.14 ± 3.93
Enjoyment Question: Before Treatment2.81 ± 3.243.12 ± 2.74
Enjoyment Question: 24 Hours After Treatment2.58 ± 3.293.34 ± 2.89
Enjoyment Question: 1 Month Post Treatment2.64 ± 3.513.09 ± 2.91
Enjoyment Question: 6 Months Post Treatment3.18 ± 3.364.00 ± 4.12
SecondaryMigraine Headache Days

Compare change in the number of migraine headache days per month reported in Baseline Period Diary vs. Treatment Period Diary vs. Post-Treatment Period Diary.

Time frame:
12 Weeks
Reported as:
Mean · Migraine headache days per month
Migraine Headache Days
Migraine headache days per monthMarcaineSaline
Baseline15.0 ± 6.3315.8 ± 7.40
Treatment12.3 ± 8.8312.2 ± 9.69
Post Treatment10.8 ± 9.2211.3 ± 8.32
SecondaryAcute Medications Usage

Number of acute medications used during Treatment period (6 weeks) and Follow-Up (4 weeks) (Group A vs. Group B).

Time frame:
10 Weeks
Reported as:
Mean · Number of medications used
Acute Medications Usage
Number of medications usedMarcaineSaline
Acute Medications Usage29.3 ± 28.247.4 ± 54.2
SecondaryAdverse Events

Number of adverse events over the entire length of study (Group A vs. Group B).

Time frame:
34 weeks
Reported as:
Mean · Number of Adverse Events
Adverse Events
Number of Adverse EventsMarcaineSaline
Adverse Events7.67 ± 8.235.29 ± 7.02
SecondaryHeadache Impact Test (HIT-6)

Total Headache Impact Test (HIT-6) scores Pre-Treatment at Visit 2 vs. Post-Treatment (following final treatment), and at 1-Month Post-Treatment (Group A vs. Group B). HIT-6 is a series of 6 likert scale questions ranging from 1 to 5 with 1 being never and 5 being always. The HIT-6 answer options are weighted as follows: Never (1) = 6 points each, Rarely (2) = 9 points each, Sometimes (3) = 10 points each, Very often (4) = 11 points each, Always (5) = 13 points each. The total score for the HIT-6 ranges from 36 (subject answers all 6 questions as "Never") to 78 subject answers all 6 questions as "Always"), with higher total scores indicating more impact than lower scores, i.e., headaches cause greater impact on the subject's life.

Time frame:
10 Weeks
Reported as:
Mean · units on a scale
Headache Impact Test (HIT-6)
units on a scaleMarcaineSaline
Pre-Treatment64.36 ± 4.9364 ± 3.92
Post-Treatment59.85 ± 8.3362.5 ± 4.96
1-Month Post-Treatment59.23 ± 8.9761.92 ± 5.45
SecondaryOverall Satisfaction

Satisfaction scores Visit 2 vs. following treatment (Treatment 12) and at 1-Month Post-Treatment (Group A vs. Group B). Satisfaction scores are a likert scale ranging from 1 to 5 with 1 being complete dissatisfaction and 5 being complete satisfaction.

Time frame:
10 Weeks
Reported as:
Mean · units on a scale
Overall Satisfaction
units on a scaleMarcaineSaline
Visit 23.52 ± 0.753.00 ± 0.89
Following treatment (Treatment 12)3.55 ± 1.002.50 ± 0.97
1-Month Post-Treatment3.57 ± 0.992.64 ± 1.12

Adverse events

Collected over Adverse events were collected from the time of signing the informed consent until study exit. The length of study participation was 34 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Marcaine—0/27 (0%)9/27 (33.3%)
Saline—1/14 (7.1%)5/14 (35.7%)
Most frequent serious events
Most frequent serious events
EventMarcaineSaline
Pulmonary Embolism Resulting in DeathCardiac disorders0/271/14
Most frequent other events
Most frequent other events
EventMarcaineSaline
ColdRespiratory, thoracic and mediastinal disorders9/272/14
LacrimationEye disorders8/271/14
Bad TasteGeneral disorders7/271/14
Mouth NumbnessGeneral disorders6/270/14
Nasal IrritationGeneral disorders4/273/14
DizzinessGeneral disorders0/272/14
Ear RingingEar and labyrinth disorders0/272/14
Light HeadednessGeneral disorders1/272/14
Sore ThroatGeneral disorders2/272/14

Baseline characteristics

Age, Continuous
Age, Continuous(years)MarcaineSalineTotal
Mean40.96 ± 11.6341.97 ± 14.7141.30 ± 12.59
Sex: Female, Male
Sex: Female, Male(Participants)MarcaineSalineTotal
Female201131
Male7310
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MarcaineSalineTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American404
White201434
More than one race303
Unknown or Not Reported000
08

Study locations

2 sites
  • Michigan Head Pain & Neurological Institute
    Ann Arbor, Michigan 48104, United States
  • Clinvest/A Division of Banyan Group, Inc.
    Springfield, Missouri 65807, United States
09

References and documents

Publications

  • Tepper SJ. A pivotal moment in 50 years of headache history: the first American Migraine Study. Headache. 2008 May;48(5):730-1; discussion 732. doi: 10.1111/j.1526-4610.2008.01117_1.x. PubMed 18471125 ↗
  • Piagkou M, Demesticha T, Troupis T, Vlasis K, Skandalakis P, Makri A, Mazarakis A, Lappas D, Piagkos G, Johnson EO. The pterygopalatine ganglion and its role in various pain syndromes: from anatomy to clinical practice. Pain Pract. 2012 Jun;12(5):399-412. doi: 10.1111/j.1533-2500.2011.00507.x. Epub 2011 Sep 29. Erratum In: Pain Pract. 2012 Nov;12(8):673. PubMed 21956040 ↗
  • Oluigbo CO, Makonnen G, Narouze S, Rezai AR. Sphenopalatine ganglion interventions: technical aspects and application. Prog Neurol Surg. 2011;24:171-179. doi: 10.1159/000323049. Epub 2011 Mar 21. PubMed 21422787 ↗
  • Windsor RE, Jahnke S. Sphenopalatine ganglion blockade: a review and proposed modification of the transnasal technique. Pain Physician. 2004 Apr;7(2):283-6. PubMed 16868606 ↗
  • Rosenberg M, Phero JC. Regional anesthesia and invasive techniques to manage head and neck pain. Otolaryngol Clin North Am. 2003 Dec;36(6):1201-19. doi: 10.1016/s0030-6665(03)00134-8. PubMed 15025017 ↗
  • Wood PB. Role of central dopamine in pain and analgesia. Expert Rev Neurother. 2008 May;8(5):781-97. doi: 10.1586/14737175.8.5.781. PubMed 18457535 ↗
  • Boivie J. Chapter 48 Central post-stroke pain. Handb Clin Neurol. 2006;81:715-30. doi: 10.1016/S0072-9752(06)80052-7. No abstract available. PubMed 18808870 ↗
  • Stankewitz A, Voit HL, Bingel U, Peschke C, May A. A new trigemino-nociceptive stimulation model for event-related fMRI. Cephalalgia. 2010 Apr;30(4):475-85. doi: 10.1111/j.1468-2982.2009.01968.x. Epub 2010 Feb 1. PubMed 19673914 ↗
  • Herrera Tolosana S, Fernandez Liesa R, Escolar Castellon Jde D, Perez Delgado L, Lisbona Alquezar MP, Tejero-Garces Galve G, Guallar Larpa M, Ortiz Garcia A. [Sphenopalatinum foramen: an anatomical study]. Acta Otorrinolaringol Esp. 2011 Jul-Aug;62(4):274-8. doi: 10.1016/j.otorri.2011.01.009. Epub 2011 Mar 22. Spanish. PubMed 21429469 ↗
  • Rusu MC. Microanatomy of the neural scaffold of the pterygopalatine fossa in humans: trigeminovascular projections and trigeminal-autonomic plexuses. Folia Morphol (Warsz). 2010 May;69(2):84-91. PubMed 20512758 ↗
  • Oomen KP, Ebbeling M, de Ru JA, Hordijk GJ, Bleys RL. A previously undescribed branch of the pterygopalatine ganglion. Am J Rhinol Allergy. 2011 Jan-Feb;25(1):50-3. doi: 10.2500/ajra.2011.25.3550. PubMed 21711979 ↗
  • Siessere S, Vitti M, Sousa LG, Semprini M, Iyomasa MM, Regalo SC. Anatomic variation of cranial parasympathetic ganglia. Braz Oral Res. 2008 Apr-Jun;22(2):101-5. doi: 10.1590/s1806-83242008000200002. PubMed 18622477 ↗
  • Gronseth G, Cruccu G, Alksne J, Argoff C, Brainin M, Burchiel K, Nurmikko T, Zakrzewska JM. Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies. Neurology. 2008 Oct 7;71(15):1183-90. doi: 10.1212/01.wnl.0000326598.83183.04. Epub 2008 Aug 20. PubMed 18716236 ↗
  • Yang lY, Oraee S. A novel approach to transnasal sphenopalatine ganglion injection. Pain Physician. 2006 Apr;9(2):131-4. PubMed 16703973 ↗
  • Kanai A, Suzuki A, Kobayashi M, Hoka S. Intranasal lidocaine 8% spray for second-division trigeminal neuralgia. Br J Anaesth. 2006 Oct;97(4):559-63. doi: 10.1093/bja/ael180. Epub 2006 Aug 1. PubMed 16882684 ↗
  • Cady RK, Saper J, Dexter K, Cady RJ, Manley HR. Long-term efficacy of a double-blind, placebo-controlled, randomized study for repetitive sphenopalatine blockade with bupivacaine vs. saline with the Tx360 device for treatment of chronic migraine. Headache. 2015 Apr;55(4):529-42. doi: 10.1111/head.12546. Epub 2015 Mar 31. PubMed 25828648 ↗
  • Cady R, Saper J, Dexter K, Manley HR. A double-blind, placebo-controlled study of repetitive transnasal sphenopalatine ganglion blockade with tx360((R)) as acute treatment for chronic migraine. Headache. 2015 Jan;55(1):101-16. doi: 10.1111/head.12458. Epub 2014 Oct 23. PubMed 25338927 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2012
First posted
Oct 18, 2012
Start
Sep 2012
Primary completionActual
Feb 2014
CompletionActual
Feb 2014
Results first posted
Oct 20, 2014
Last update
Jan 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01709708
Lead sponsor
Tian Medical Inc.
Collaborators
Clinvest
Responsible party
Sponsor
First posted
Oct 18, 2012
Start date
Sep 2012
Primary completion
Feb 2014
Completion
Feb 2014
Results posted
Oct 20, 2014
Last update
Jan 26, 2018

Study contacts

Tian Xia, MD
principal investigator · Tian Medical Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion